NurExone Biologics has been named a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. With plans to move into clinical trials next year with an exosome therapy for spinal cord injuries, Diana Turner caught up Dr Lior Shaltiel, CEO… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all shine a light on… Read More
News round-up for 2-6 December by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all shine a light on innovation within drug discovery, including a potential ‘best-in-industry’ weight loss drug, a gold-based compound that shrinks tumours by 82%, and a second-generation CAR-T therapy. Read More
EXO Biologics (and its CDMO subsidiary, ExoXpert) has announced it has received Good Manufacturing Practice (GMP) certification for its manufacturing plant in Liège, Belgium. In addition, the company says it has managed to achieve the loading of GMP-grade exosomes with mRNA and DNA payloads, describing it as… Read More
EXO Biologics has completed dosing of the first cohort of patients in its EVENEW study, the first European Medicines Agency (EMA) authorised clinical trial involving mesenchymal stromal cell (MSC)-based exosomes. The Phase I/II clinical trial is testing the company’s lead candidate EXOB-001, developed to prevent bronchopulmonary… Read More
Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Lack of standardisation According to Hummersone, the major challenge in the CGT space is a lack of throughput that’s due to… Read More
EXO Biologics has launched ExoXpert, a contract development and manufacturing organisation (CDMO) specialising in exosomes which offers a mesenchymal stem cells (MSC)-based exosome manufacturing platform used in European clinical trials. During the development of its lead exosome candidate, EXOB-001, Exo Biologics developed ExoPulse, an industrial exosome manufacturing… Read More
Evox Therapeutics, an exosome therapeutics company, has published Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes in Nature Communications. This follows a research collaboration and option agreement with the Icahn School of… Read More
